A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

December 11, 2018

Primary Completion Date

August 9, 2021

Study Completion Date

September 9, 2021

Conditions
Multiple Sclerosis (MS)
Interventions
DRUG

elezanumab

solution for infusion

DRUG

placebo

solution for infusion

Trial Locations (49)

19107

Thomas Jefferson University /ID# 204281, Philadelphia

21225

Duplicate_Parexel International /ID# 204273, Baltimore

22310

Integrated Neurology Services, PLLC /ID# 204261, Alexandria

26506

West Virginia Univ School Med /ID# 204292, Morgantown

35233

University of Alabama at Birmingham - Main /ID# 204618, Birmingham

37064

Advanced Neurosciences Institute /ID# 204557, Franklin

37604

Tri-State Mountain Neurology /ID# 204252, Johnson City

46202

Indiana Univ School Medicine /ID# 204891, Indianapolis

48334

Michigan Institute for Neurological Disorders (MIND) /ID# 204194, Farmington Hills

63110

Washington University-School of Medicine /ID# 204388, St Louis

66214

Rowe Neurology Institute /ID# 204391, Lenexa

70810

The NeuroMedical Center /ID# 204253, Baton Rouge

73104

Oklahoma Med Res. Foundation /ID# 204389, Oklahoma City

78681

Central Texas Neurology Consul /ID# 204268, Round Rock

79410

Dr. Bhupesh Dihenia, MD, PA /ID# 207839, Lubbock

80528

Advanced Neurosciences Research, LLC /ID# 204289, Fort Collins

85013

St. Josephs Hospital and Med Center /ID# 204197, Phoenix

92697

UC Irvine Health /ID# 205728, Irvine

98101

Virginia Mason Medical Center /ID# 205440, Seattle

94705-2017

Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249, Berkeley

92011-4213

The Research Center of Southern California /ID# 204269, Carlsbad

93230-5787

Vladimir Royter MD /ID# 204392, Hanford

94304-1416

Stanford MS Center /ID# 204283, Palo Alto

95817-2307

UC Davis Health-Neurological Surgery /ID# 204188, Sacramento

94143-0003

UCSF School of Medicine - Neurology /ID# 204251, San Francisco

80045-2527

University of Colorado School of Medicine /ID# 204250, Aurora

60637-1443

The University of Chicago Medical Center /ID# 205319, Chicago

70121-2429

Ochsner Medical Center /ID# 204189, New Orleans

21093-6016

International Neurorehabilitation Institute /ID# 213332, Lutherville

02114

Pediatric Endocrine Associates /ID# 204279, Boston

48867-2116

Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206328, Owosso

55318-4551

Ridgeview Specialty Clinic Chaska - Neurology /ID# 204383, Chaska

63131-2322

The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205433, St Louis

89106-0100

Cleveland Clinic Lou Ruvo Cent /ID# 204745, Las Vegas

97225-6646

Providence Neurological Specialties - West /ID# 204248, Portland

37067-5914

KCA Neurology - Franklin /ID# 204208, Franklin

75243-1188

Neurology Consultants of Dallas - LBJ Fwy /ID# 204398, Dallas

77030-1501

UT HSC Multiple Sclerosis Research Group - Houston /ID# 206418, Houston

98034-3029

Evergreen Neuroscience Institute /ID# 204203, Kirkland

98122-5698

Swedish MS Center /ID# 204198, Seattle

98133-8400

University of Washington Medicine MS Center /ID# 205852, Seattle

53226-3522

Froedtert Memorial Lutheran Hospital /ID# 204202, Milwaukee

V6T 1Z3

University of British Columbia - MS & NMO Clinical Trials Group, Djavad Mowafagh /ID# 204841, Vancouver

N6A 5A5

Duplicate_London Health Sciences Centre - University Hospital /ID# 204848, London

K1H 8L6

Ottawa Hospital Research Institute /ID# 204842, Ottawa

M5B 1W8

Unity Health Toronto - St. Michael's Hospital /ID# 206214, Toronto

J4V 2J2

Recherche Sepmus Inc. /ID# 212851, Greenfield Park

H2X 0A9

Centre Hospitalier de l'Universite de Montreal - CRCHUM /ID# 204844, Montreal

H3A 2B4

Montreal Neurological Institut /ID# 204843, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY